News Releases - CSL
WEB6 days ago · Find out the latest news from CSL, a global biotechnology company with three operating divisions: CSL Behring, CSL Seqirus and CSL Vifor. Read about their products, partnerships, approvals, innovations and achievements in various fields and regions.
News Releases - CSL
WEBApr 17, 2024 · CSL is a leading biotechnology company with products in plasma, vaccines and gene therapies. Read the latest news on CSL's financial results, COVID-19 vaccine, gene therapy for hemophilia B and more.
Global Newsroom | CSL
WEBCSL is a global biotechnology company with four operating divisions: CSL Behring, CSL Seqirus, CSL Vifor and CSL. Read the latest news from CSL and its subsidiaries on topics such as COVID-19, CIDP, IgA nephropathy and more.
News Releases | CSL
WEBDec 14, 2021 · CSL Limited, a global biotechnology leader, announces a US$11.7 billion all-cash tender offer to acquire Vifor Pharma Ltd, a global specialty pharmaceutical company with leadership in iron deficiency and nephrology. The transaction is expected to be accretive, diversify CSL's business model and expand its pipeline and market opportunities.
New COVID-19 sa-mRNA Results from CSL and Arcturus …
WEBFeb 5, 2024 · The study shows that ARCT-154, the world's first approved self-amplifying messenger RNA (sa-mRNA) COVID-19 vaccine, induces longer immune response and antibody persistence than conventional mRNA vaccine. The data follows the approval of ARCT-154 in Japan and supports its potential for lower doses and broader protection.
News Releases - CSL
WEBFeb 7, 2022 · Seqirus, a global leader in influenza prevention and a business of CSL Limited, announced an investment in a new Research and Development facility in Waltham, Mass. The facility will support the company’s growing R&D portfolio, including the self-amplifying mRNA technology platform, the next generation of mRNA vaccine technology, for seasonal and pandemic influenza vaccines.
News Releases | CSL
WEBPrime Minister Anthony Albanese officially opened CSL's new facility in the Parkville biomedical precinct, a A$2 billion investment in Australia's scientific and medical innovation. The state-of-the-art building houses CSL's research and development teams and supports local biotech start-ups.
Global Biotechnology Company | CSL
WEBCSL is a leading provider of biotech products and services for patients and public health. Learn about its four businesses: CSL Behring, CSL Plasma, CSL Seqirus and CSL Vifor, and their latest news, innovations and careers.
News Releases - CSL
WEBMay 30, 2024 · CSL Limited (ASX: CSL) Today, CSL advances its vision for a more sustainable future by setting new, tangible targets for carbon emissions reductions. As part of the company's broader... Aug 10, 2022
News Releases - CSL
WEBGaradacimab is a first-in-class monoclonal antibody that targets FXIIa, a key protein in the HAE cascade. A Phase 3 study showed that garadacimab reduced HAE attacks by 86.5% compared to placebo and was well tolerated.